RE:RE:Pelareorep in 3rd line HR+/HER2 negative breast cancerThe reported incidence of breast cancer is currently based on 2022 numbers,which approximates 685,700 women being diagnosed with invasive breast cancer just in the United States and the EU -27.
On 2022 global numbers - HR+/HER2 negative breasat cancer accounts for approximately 65% of all breast cancers (60-70%), thus translating into approximately 446,000 women who are diagnosed each year with HR+/HER2 negative breast cancer in the US and EU-27.
Out of the approximate 446,000 women newly diagnosed HR+/HER2 negative breast cancer each year, ONCY has estimated that approximately 55,000 of these women will progress to 3rd line mBC therapy which ONCY has stated will be eligible for pelareorep (monotherapy) + paclitaxel treatment.